Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	e of entity		ABN/ARSN	
Sig	ma Pharmaceuticals Limited		15 088 417 403	
We	(the entity) give ASX the following	information.		
Inf	ormation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 18 November 2015)		
	tal of all shares/units bought we been received, before, and	-	_	
		on, previous day	_	
hav	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been	on, previous day Before previous day	Previous day	

Before previous day			Previous day			
Highest \$0.8700	price	paid		ghest 8600	price	paid:
			Lov	west p	rice pa	id:

paid:

\$0.8400

\$0.8830

Highest price allowed under rule 7.33:

price

5 If buy-back is an on-market buyback

How many shares/units may still be bought back?

6	If the company/trust has disclosed
	an intention to buy back a
	maximum number of shares/units
	- the remaining number of
	shares/units to be bought back

7,708,932			

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

Lowest

\$0.5600

2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 30 November 2015

(Director/Company secretary)

Print name: JEFF SELLS

== == == ==